Bio-Plexus Signs New Specialty Dealer Agreements to Support Launch of PUNCTUR-GUARD(R) Safety Winged Set for Blood Collection.

Business Editors

VERNON, Conn.--(BUSINESS WIRE)--Oct. 2, 2001

Bio-Plexus, Inc. (OTCBB: BPXS) a leader in the design, manufacture and marketing of safety medical needles, today announced the signing of distribution agreements with eight new medical products specialty dealers.

These new relationships will support the launch of the Company's PUNCTUR-GUARD(R) Winged Set for Blood Collection safety needle. As a result of these agreements, 40 sales professionals will begin marketing the PUNCTUR-GUARD product in 24 states. It is anticipated that revenues generated from sales of this product through these new specialty dealers will be realized beginning in the fourth quarter of fiscal 2001.

Christopher Zorn, Executive Vice President of Sales at Bio-Plexus, commented, "These agreements more than double Bio-Plexus' base of domestic specialty distributors and resultant sales capacity. Each of these companies brings significant experience and track records of success in safety medical product sales. They will complement and enhance our own direct clinical sales team and speed the penetration of the PUNCTUR-GUARD Winged Set into a wider range of geographic markets. We believe that it is vital that Bio-Plexus increase its visibility and sales support coverage in the marketplace during a time of increasing need for effective safety winged set alternatives and other safety blood collection products."

The distributors include:

      -- Capitol Medical Inc., based in Harrisburg, PA
      -- CoMedical, Inc. of Seattle, WA
      -- Bimeco, A PrimeSource Surgical Company of Bessemer, AL
      -- Northstar Medical System, based in Shoreview, MN
      -- Promed Medical Corp, located in Englewood, CO
      -- Clinical Technology Inc. of Broadview Heights, OH
      -- Amtec Medical, Inc., based in Austin, TX
      -- Medtec Medical, based in Buffalo Grove, IL

John S. Metz, President of Bio-Plexus, stated, "The PUNCTUR-GUARD Winged Set for Blood Collection will be a significant revenue producer for Bio-Plexus. Market share reports indicate that the size of the total U.S. market for both safety and non-safety winged sets is $160 million annually. The conversion to safety needles in blood collection or blood sampling is below 50% but expanding rapidly, due to federal and state legislation aimed at ensuring that health care workers have unprecedented access to safety needles."

Brian Usko, President of Capitol Medical, commented, "We have surveyed the product landscape and found that Bio-Plexus' PUNCTUR-GUARD Winged Set for Blood Collection and the other products in the line offer the highest level of protection for healthcare workers against accidental needlesticks. Our customers are demanding, with increasing frequency, the type products being offered by Bio-Plexus. We are excited to be representing the Company."

Bio-Plexus launched the PUNCTUR-GUARD(R) Winged Set for Blood Collection in July 2001. This followed the Company's receipt of 510(k) approval from the Food and Drug Administration in January 2001 and the successful clinical evaluations of the product undertaken by Bio-Plexus since May 2001. Winged sets are steel hollow bore needles with attached tubing used for blood collection. The PUNCTUR-GUARD Winged Set incorporates the same internal blunting technology used in the Company's PUNCTUR-GUARD multi-sample blood collection needle. Upon activation, an inner hollow blunt needle extends beyond the sharp point of the outer needle prior to removal of the device from the patient, thereby eliminating the exposure to sharp, contaminated needles. Current devices require removal of the contaminated sharp needle from the patient before the outer sheath can be moved into place over the contaminated needle.

Bio-Plexus, Inc., designs, develops, manufactures and holds U.S. and international patents on safety medical needles and other products under the PUNCTUR-GUARD(R), DROP-IT(R), and PUNCTUR-GUARD REVOLUTION(TM) brand names. For independent evaluations of the PUNCTUR-GUARD(R) blood collection needle, refer to the Centers for Disease Control (MMWR, January 1997) and ECRI (Health Devices, June 1998 and October 1999) studies. Accidental needlesticks number about one million per year in the United States and can result in the transmission of deadly diseases including HIV and Hepatitis B and C.

"Note; this press release contains forward-looking statements within the meaning of the private securities litigation reform act of 1995. Forward looking statements are identified by the use of such terminology as "believes," "expects," "may," "should," "anticipates," "plans," "estimates," and "intends," or derivations or negatives thereof or comparable terminology. Accordingly, such statements involve risks (known and unknown) and uncertainties. These risks and uncertainties include the company's ability to timely and fully implement its bankruptcy court confirmed plan of reorganization; the consummation of the private placement financing provided for in the plan; the availability of sufficient capital to fund the company's operations pending consummation of that financing; the continued willingness of the company's customers, vendors and employees to maintain their relationships with the company during this period; the acceptance of the company's products by health care professionals; the company's ability to protect its propriety technology; availability of qualified personnel; changes in, or failure to comply with government regulations; the risks associated with expanding the company's business internationally; and general economic and business conditions. the company undertakes no obligation to update or advise upon any such forward-looking statement.